Yingping Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yingping Xu has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Bin Yang
Dermatology Hospital of Southern Medical University Guangzhou Guangdong China
4 shared publications - Ping Lu
Dermatology Hospital Southern Medical University Guangzhou China
3 shared publications Chuanwei Li
Southern Med Univ, Dermatol Hosp, Inst Dermatol & Venereol, Guangzhou 510091, Peoples R China
2 shared publicationsHaosen Song
Southern Med Univ, Dermatol Hosp, Inst Dermatol & Venereol, Guangzhou 510091, Peoples R China
2 shared publications- Huifang Guo
Guangzhou Med Univ, State Key Lab Resp Dis, Affiliated Canc Hosp & Inst, Guangzhou 510091, Peoples R China
2 shared publications - Jun Liu
Dermatology Hospital Southern Medical University Guangzhou China
2 shared publications
Latest Publications
- Open Access
Impact of Dupilumab Therapy on Skin Barrier Function in Patients With Moderate‐to‐Severe Atopic Dermatitis: A Phase IV, Non‐Randomized, Open‐Label, Parallel‐Group Clinical Study
Dupilumab improves skin barrier function in patients with atopic dermatitis (AD), but data for Chinese patients are limited. This 16‐week, prospective, exploratory study investigated the impact of dupilumab on skin barrier function in Chinese patients with moderate‐to‐severe AD. Forty‐four participants (24 patients with AD and 20 healthy volunteers) were enrolled. Patients with AD received dupilumab treatment every 2 weeks and were followed up to Week 16. Tape‐stripped stratum corneum samples were collected from participants at seven specific time points for proteomic and lipidomic profiling, together with transepidermal water loss (TEWL) measurement. At Week 16, TEWL after five tape strips was significantly reduced versus baseline (adjusted p = 0.0006). Proteomics revealed significant upregulation of sphingolipid and other lipid metabolism pathways within the first 2 weeks, coinciding with early TEWL improvement; keratinocyte differentiation and keratinization pathways were enriched from Week 8 through Week 16. Lipidomics revealed that specific dysregulated ceramides—CER(d16:0/16:0), CER(d16:0/20:3), CER(t20:1/23:0), and CER(t20:1/24:1)—showed significant changes by Weeks 2–8 and completely normalized by Week 16. Dupilumab improved skin barrier function in Chinese patients with moderate‐to‐severe AD, accompanied by dynamic molecular changes; these correlative findings require functional validation to establish causality. Trial Registration: ClinicalTrials.gov NCT05624112.
Open AccessImpact of Dupilumab Therapy on Skin Barrier Function in Patients With Moderate‐to‐Severe Atopic Dermatitis: A Phase IV, Non‐Randomized, Open‐Label, Parallel‐Group Clinical Study
Dupilumab improves skin barrier function in patients with atopic dermatitis (AD), but data for Chinese patients are limited. This 16‐week, prospective, exploratory study investigated the impact of dupilumab on skin barrier function in Chinese patients with moderate‐to‐severe AD. Forty‐four participants (24 patients with AD and 20 healthy volunteers) were enrolled. Patients with AD received dupilumab treatment every 2 weeks and were followed up to Week 16. Tape‐stripped stratum corneum samples were collected from participants at seven specific time points for proteomic and lipidomic profiling, together with transepidermal water loss (TEWL) measurement. At Week 16, TEWL after five tape strips was significantly reduced versus baseline (adjusted p = 0.0006). Proteomics revealed significant upregulation of sphingolipid and other lipid metabolism pathways within the first 2 weeks, coinciding with early TEWL improvement; keratinocyte differentiation and keratinization pathways were enriched from Week 8 through Week 16. Lipidomics revealed that specific dysregulated ceramides—CER(d16:0/16:0), CER(d16:0/20:3), CER(t20:1/23:0), and CER(t20:1/24:1)—showed significant changes by Weeks 2–8 and completely normalized by Week 16. Dupilumab improved skin barrier function in Chinese patients with moderate‐to‐severe AD, accompanied by dynamic molecular changes; these correlative findings require functional validation to establish causality. Trial Registration: ClinicalTrials.gov NCT05624112.
- 10 March 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (9) , 2465-2474.e7
Basophil activity in atopic dermatitis: Distinct immunomodulatory roles of dupilumab and abrocitinib
- 10 March 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (9) , 2465-2474.e7
Basophil activity in atopic dermatitis: Distinct immunomodulatory roles of dupilumab and abrocitinib
- Open Access
- 23 April 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 133, 112012
Mitochondrial-dependent oxidative phosphorylation is key for postnatal metabolic adaptation of alveolar macrophages in the lung
- 23 April 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 133, 112012
Open AccessMitochondrial-dependent oxidative phosphorylation is key for postnatal metabolic adaptation of alveolar macrophages in the lung
- Open Access
- 1 January 2024
- Published by Ivyspring International Publisher in Theranostics
- Vol. 14 (5) , 2232-2245
Dynamic pathological analysis reveals a protective role against skin fibrosis for TREM2-dependent macrophages
Rationale: Systemic sclerosis (SSc) is a chronic and incurable autoimmune disease with high mortality rates, and skin fibrosis is one of distinguishing hallmarks in the pathogenesis. However, macrophage heterogeneity regulating skin fibrosis remain largely unknown.
- 1 January 2024
- Published by Ivyspring International Publisher in Theranostics
- Vol. 14 (5) , 2232-2245
Open AccessDynamic pathological analysis reveals a protective role against skin fibrosis for TREM2-dependent macrophages
Rationale: Systemic sclerosis (SSc) is a chronic and incurable autoimmune disease with high mortality rates, and skin fibrosis is one of distinguishing hallmarks in the pathogenesis. However, macrophage heterogeneity regulating skin fibrosis remain largely unknown.
- 22 November 2022
- Published by Wiley in Clinical Genetics
- Vol. 103 (3) , 301-309
Loss‐of‐function mutations in CST6 cause dry skin, desquamation and abnormal keratosis without hypotrichosis
Cystatin M/E (encoded by the CST6 gene) is a cysteine protease inhibitor, that exerts regulatory and protective effects against uncontrolled proteolysis mainly by directly regulating cathepsin V, cathepsin L, and legumain activities. Previous studies have suggested that CST6 may exert a regulatory role in epidermal differentiation and hair follicle formation by inhibiting the activity of respective cognate target proteases. However, until recently, studies have revealed that loss‐ or gain‐of‐function of the CST6 gene causes dry skin with hypotrichosis in humans. Here, we reported two siblings of Chinese origin with dry skin, desquamation and abnormal keratosis without hypotrichosis. By applying whole‐exome sequencing, we identified homozygous loss‐of‐function mutation c.251G > A (p.Gly84Asp) in the CST6 gene as the underlying genetic cause. Further fluorimetric enzyme assays demonstrated the mutant cystatin M/E protein lost its inhibitory function on the protease activity of cathepsins. Moreover, the corresponding mutation in mice resulted in excessive cornification, desquamation, impaired skin barrier function, and abnormal proliferation and differentiation of keratinocytes. In conclusion, the homozygous missense mutation c.251G > A in CST6 gene resulted in dry skin, desquamation, as well as abnormal keratosis of the skin, promoting our understanding of the role of protease‐antiprotease balance in human skin disorders.
- 22 November 2022
- Published by Wiley in Clinical Genetics
- Vol. 103 (3) , 301-309
Loss‐of‐function mutations in CST6 cause dry skin, desquamation and abnormal keratosis without hypotrichosis
Cystatin M/E (encoded by the CST6 gene) is a cysteine protease inhibitor, that exerts regulatory and protective effects against uncontrolled proteolysis mainly by directly regulating cathepsin V, cathepsin L, and legumain activities. Previous studies have suggested that CST6 may exert a regulatory role in epidermal differentiation and hair follicle formation by inhibiting the activity of respective cognate target proteases. However, until recently, studies have revealed that loss‐ or gain‐of‐function of the CST6 gene causes dry skin with hypotrichosis in humans. Here, we reported two siblings of Chinese origin with dry skin, desquamation and abnormal keratosis without hypotrichosis. By applying whole‐exome sequencing, we identified homozygous loss‐of‐function mutation c.251G > A (p.Gly84Asp) in the CST6 gene as the underlying genetic cause. Further fluorimetric enzyme assays demonstrated the mutant cystatin M/E protein lost its inhibitory function on the protease activity of cathepsins. Moreover, the corresponding mutation in mice resulted in excessive cornification, desquamation, impaired skin barrier function, and abnormal proliferation and differentiation of keratinocytes. In conclusion, the homozygous missense mutation c.251G > A in CST6 gene resulted in dry skin, desquamation, as well as abnormal keratosis of the skin, promoting our understanding of the role of protease‐antiprotease balance in human skin disorders.
- 29 August 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (3) , 508-513.e2
TFAM Deficiency‒Mediated Mitochondrial Disorder Affects Langerhans Cell Maintenance and Function
- 29 August 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (3) , 508-513.e2
TFAM Deficiency‒Mediated Mitochondrial Disorder Affects Langerhans Cell Maintenance and Function
- 1 November 2021
- Published by Elsevier in Journal of Dermatological Science
- Vol. 104 (2) , 95-103
Oncostatin M sensitizes keratinocytes to UVB-induced inflammation via GSDME-mediated pyroptosis
- 1 November 2021
- Published by Elsevier in Journal of Dermatological Science
- Vol. 104 (2) , 95-103
Oncostatin M sensitizes keratinocytes to UVB-induced inflammation via GSDME-mediated pyroptosis
- Open Access
- 1 August 2021
- Published by Elsevier in Cell Reports
- Vol. 36 (6) , 109524
Single-cell transcriptome analysis reveals the dynamics of human immune cells during early fetal skin development
- 1 August 2021
- Published by Elsevier in Cell Reports
- Vol. 36 (6) , 109524
Open AccessSingle-cell transcriptome analysis reveals the dynamics of human immune cells during early fetal skin development
- 1 April 2021
- Published by Elsevier in Annals of Oncology
- Vol. 32 (4) , 578
Corrigendum to “Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer”
- 1 April 2021
- Published by Elsevier in Annals of Oncology
- Vol. 32 (4) , 578
Corrigendum to “Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer”
- 1 September 2019
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 139 (9) , 1925-1935.e5
TRAF4 Promotes Fibroblast Proliferation in Keloids by Destabilizing p53 via Interacting with the Deubiquitinase USP10
- 1 September 2019
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 139 (9) , 1925-1935.e5
TRAF4 Promotes Fibroblast Proliferation in Keloids by Destabilizing p53 via Interacting with the Deubiquitinase USP10